SH-327

SH-327 is a highly selective, orally bioavailable small molecule inhibitor of phosphoinositide 3-kinase gamma (PI3Kgamma) developed by the University of Michigan. It is designed to target the tumor immunosuppressive microenvironment by polarizing M2-like tumor-associated macrophages (TAMs) to pro-inflammatory M1-like macrophages, reducing myeloid-derived suppressor cells (MDSCs), and enhancing cytotoxic CD8+ T cell activity. Preclinically, SH-327 has demonstrated superior anti-tumor efficacy and tissue distribution (with higher concentrations in tumors, spleen, and tumor-draining lymph nodes and lower plasma levels) compared to the PI3Kgamma inhibitor IPI-549, thereby potentially reducing pan-PI3K inhibitor-related toxicities. It is being investigated for the treatment of solid tumors, such as breast cancer and colon cancer, as well as autoimmune diseases like lupus.

Other names

SH327SH-327SH 327